Literature DB >> 15038803

An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand.

Verity Humberstone1, Amanda Wheeler, Tim Lambert.   

Abstract

OBJECTIVE: To examine antipsychotic usage in outpatients in three community mental health centres.
METHOD: A retrospective chart review was conducted for all outpatient files that were active in March 2000 at all community mental health services in Auckland (population 1.3 million). All patients prescribed an antipsychotic had information entered into a specifically designed computer software program. The antipsychotic, dose and route of administration were recorded. The diagnosis, number of hospitalizations, ethnicity and gender were also collected.
RESULTS: 6558 community files were audited and 3254 people were prescribed antipsychotics; 3178 (97.6%) files had adequate information for study inclusion. The mean antipsychotic daily dose in chlorpromazine equivalents (CPZe) was 360 mg. Most of the population (76.6%) was prescribed an oral antipsychotic alone, 14.9% were prescribed depot antipsychotic only and 8.4% were on a depot and oral antipsychotic. The average daily dose prescribed for people on antipsychotic polypharmacy was 601 mg CPZe compared with 312 mg CPZe for those on a single antipsychotic. There were 2300 patients with schizophrenia (72.5% of cohort) and 585 patients with bipolar affective disorder (18.5%). The mean total daily dose in CPZe was significantly higher for schizophrenia than any other psychotic diagnoses. Regional analysis showed differences in the doses and type of antipsychotics prescribed; one health sector had significantly higher daily doses while another was significantly more likely to prescribe atypical antipsychotics and correspondingly fewer depot antipsychotics.
CONCLUSIONS: There is a significant variation in the prescribing of antipsychotics across the three Auckland health sectors. The variation relates to dosage used, type of antipsychotics prescribed and effect of multiple antipsychotic prescribing. Combination therapy of more than one oral antipsychotic or a combination of oral and depot antipsychotics leads to a significant trend of higher doses in excess of best practice guidelines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15038803     DOI: 10.1080/j.1440-1614.2004.01340.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  15 in total

Review 1.  Drug utilization review across jurisdictions--a reality or still a distant dream?

Authors:  Lisa K Pulver; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2006-01-10       Impact factor: 2.953

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 4.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

5.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

6.  Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Authors:  Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

7.  Relationship between depressive symptoms and quality of life in Nigerian patients with schizophrenia.

Authors:  Adesanmi Akinsulore; Olutayo O Aloba; B M Mapayi; I O Oloniniyi; F O Fatoye; R O A Makanjuola
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

Review 8.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

9.  Visual processing of social context during mental state perception in schizophrenia.

Authors:  Melissa J Green; Jennifer H Waldron; Ian Simpson; Max Coltheart
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

Review 10.  Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Authors:  William G Honer; Allen E Thornton; Megan Sherwood; G William MacEwan; Tom S Ehmann; Richard Williams; Lili C Kopala; Ric Procyshyn; Alasdair M Barr
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.